YOLFTbeta
08

ISU Abxis Co. Ltd

086890 · KQ · Healthcare / Pharmaceuticals

3,215.00KRW-90.00 (-2.72%)

Price History

Full chart

Market Stats

Previous Close3,305.00
Open3,340.00
Day Range3,190.00 – 3,370.00
52-Week Range2,890.00 – 6,350.00
Volume83.79K
Market Cap156.78B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.97
50-Day Avg3,445.10
200-Day Avg4,324.65

About

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; and Clotinab, an abciximab that is used as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications. It is also developing ISU104, a human antibody for the treatment of refractory cancer; ISU304, a modified recombinant factor IX protein for the treatment of Hemophilia B patients; and ISU305, an antibody biosimilar for paroxysmal nocturnal hemoglobinuria therapy. ISU Abxis Co., Ltd. is headquartered in Seongnam, South Korea.

Company Details

  • SectorHealthcare
  • IndustryPharmaceuticals
  • CEOSang-Ho Park Ph.D.
  • Employees0
  • HeadquartersGlobal R&D Center Building C, Seongnam-si, South Korea, 13488, Korea
  • Websitehttps://www.abxis.com

Leadership

  • Sang-Ho Park Ph.D.Chief Exec. Officer · b. 1962
  • Chang-Hoon ChoiExec. · b. 1960
  • Mr. Heung-Rok ParkExec. · b. 1963
  • Joon-Young ParkExec.
  • Mr. Seungho KimExec. · b. 1966
  • Young-Soo SohnExec. · b. 1953
  • Mr. Sung-Ho ChoiExec.
  • Jin-Chul ShinExec. · b. 1967
  • Hyun-Il KimExec.
  • Jae-Heung LeeExec.

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue7.10B11.47B19.05B19.46B16.75B21.02B25.61B28.02B41.17B54.31B60.26B56.67B
Growth (%)-+61.63%+66.11%+2.12%-13.94%+25.52%+21.83%+9.42%+46.94%+31.91%+10.96%-5.95%
Cost of Revenue3.28B5.38B7.42B9.26B9.14B13.51B14.29B16.98B28.02B18.92B16.91B26.17B
Gross Profit3.82B6.09B11.64B10.20B7.61B7.51B11.32B11.03B13.15B35.38B43.35B30.50B
Gross Margin53.81%53.06%61.07%52.41%45.43%35.74%44.21%39.38%31.94%65.15%71.93%53.82%
Operating Expense10.16B11.18B12.43B18.25B20.18B23.34B24.51B21.27B28.45B31.50B50.86B28.87B
Operating Income-6.34B-5.09B-792.05M-8.05B-12.57B-15.83B-13.19B-10.24B-15.30B3.89B-7.51B1.63B
Operating Margin-89.33%-44.39%-4.16%-41.36%-75.08%-75.31%-51.50%-36.53%-37.16%7.16%-12.47%2.88%
EBITDA--------5.60B18.68B7.64B-378.90M
EBITDA Margin--------13.61%34.39%12.68%-0.67%
Net Income-11.20B-9.77B-2.04B-8.73B-12.99B-17.82B-19.87B829.93M-7.25B3.61B14.72B-10.68B
Net Income Margin-157.78%-85.20%-10.70%-44.86%-77.57%-84.76%-77.58%2.96%-17.60%6.65%24.42%-18.84%
R&D4.29B5.34B7.67B9.88B10.10B12.60B12.65B7.57B13.37B15.21B9.45B7.29B
R&D as % of Total Revenue60.49%46.55%40.27%50.80%60.31%59.92%49.40%27.01%32.47%28.01%15.68%12.87%
Interest Expense0000006.46B4.00B7.42B9.88B8.61B7.15B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%25.22%14.29%18.02%18.20%14.29%12.62%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets48.99B70.00B59.84B77.77B69.84B92.76B82.75B151.09B137.27B206.74B160.23B158.90B
Total Liabilities31.59B23.41B14.26B15.71B10.11B37.58B39.17B79.14B72.86B129.55B59.37B44.44B
Total Equity17.41B46.59B45.58B62.05B59.73B55.18B43.57B71.95B64.41B77.19B100.86B114.46B
Cash11.61B6.33B12.52B16.77B12.12B10.12B11.46B1.61M1.57M96.33B2.02M22.64B
Total Debt-12.89B8.37B7.65B1.80B24.52B25.02B-----
Net Debt-----14.38B12.12B8.75B9.35B16.22B16.24B4.47B

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-11.49B-3.88B-2.71B-6.89B-13.38B-13.15B-8.56B-5.84B-401.66M-2.69B2.54B11.04B
Investing Cash Flow-2.08B-26.21B18.61B-15.45B4.73B-26.51B9.96B-70.58B8.11B19.33B6.74B-
Financing Cash Flow2.53B24.87B-10.02B26.68B4.43B38.24B-1.14B79.33B-775.10M58.56B-81.07B-
Capital Expenditure1.36B813.77M1.84B2.69B6.06B2.12B613.58M840.18M10.17B10.45B11.88B11.13B
Free Cash Flow-------14.53B-7.60B-10.57B-13.14B-9.34B-89.74M
FCF to OCF------169.67%130.13%2630.97%488.31%-368.04%-0.81%

Earnings

Report DateMar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Nov 14, 2014Mar 31, 2015Apr 1, 2015Jul 15, 2015Nov 17, 2015Feb 3, 2016May 11, 2016Aug 7, 2016Nov 6, 2016Feb 9, 2017May 10, 2017Aug 9, 2017Nov 7, 2017Feb 9, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Feb 7, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Feb 10, 2020Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------------------------------------------------------
EPS Actual-134.64-279.69-119.56-133.74-83.78-81.78-93.54-267.81-98.73-96.93-117.30-109.37-138.55-111.92-154.06-104.46-225.63-108.59-202.56-95.19-156.31-288.95-160.56-138.56-114.05-126.66-256.18-94.22-55.9913.55-5.22-50.99-102.482.23-37.64-126.00-95.55-153.27-68.04-158.55-129.12-101.06-142.08-297.51-171.20-143.72-94.00-316.58-127.00-25.62-99.96265.65-161.04-57.87-37.4938.01-141.01-2.195.99245.13-473.1557.7831.33730.13-244.01181.45-6.51-268.59-4.9627.50
Surprise----------------------------------------------------------------------
Timing----------------------After-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market--------------------------

Key Statistics & Ratios

Market Cap156.78B
Enterprise Value141.81B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.95
Price / Book1.21
Revenue (TTM)39.65B
Gross Profit (TTM)10.75B
EBITDA-3.73B
Profit Margin0.77%
Operating Margin-22.13%
Return on Equity2806.31%
Return on Assets-3.55%
Shares Outstanding26.63M
Shares Float21.96M
Beta0.97
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 19, 2017902:859
  • Jun 22, 2015574:541